COSCIENS Biopharma Inc T.AEZS

It's been 70 days...

[prophetoffactz]

70 days ago after completing three trial runs CZO said the 50L PGX scale-up was "almost completed". After three trial runs they should have a good idea if the quality of the product is to standard and maybe even if the quality was replicated with a second trial run. One month later, in a news release, CZO expected that pending Health Canada approval that the product could be available by year-end. That doesn't leave much time. Could there be an announcement that AEZS is preparing a filing for Health Canada approval of its first PGX product? The 40 million dose immune booster plant previously had a $100 million net present value. Last November it was also announced that an animal trial protocol for the immune booster had been designed. Previously the 50L scale-up was expected to provide materials for potential partners. Could there be an announcement that a potential partner has received PGX materials? Commissioning of the 100L PGX scale-up was also expected to be completed in Q3 with industry leader Natex and that is the decision point for mass industrialization of PGX. Last AGM Gilles said they were having discussions with serious potential partners who understood the unique selling point of bioavailability for CoQ10. With the recent completion of the merger AEZS is now optimized to bring transformational products to market according to Ronnie Miller. Ronnie has repeatedly said he was "thrilled" with the merger. AEZS has also sent a comprehensive article to the leading industry journal Biomaterials for peer-review. Previously Dr. Martin Kolb said that if preclinical results were replicated in humans it could profoundly change the treatment landscape.

April 29, 2024 news release:

• Edmonton Main Facility - PGX Scale-Up 50 Liters Vessel: This project is almost completed. Three trial runs of yeast beta glucan have been performed as part of the last commissioning phase. Given that the Edmonton site license is for natural products, yeast beta glucan produced from this facility will be offered as a nutraceutical. Subject to approval by Health Canada, this product could be launched by end of 2024.
   
• Natex Facility, Austria - PGX Scale-Up 100 Liters Vessel: The project is on schedule. PGX pressure vessel design is 100% completed. Initial safety and regulatory risk assessment has also been completed. Commissioning is expected to be completed by end of Q3 2024